Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of BGM0504 tablets in non-diabetic overweight or obese adults
CTR20261844Phase 2Active
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Jun 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity and Overweight comparing BGM0504 tablets with Placebo (2 arms). Primary endpoint: Percent change from baseline in fasting body weight. Started Jun 2026; status: active.
02
Drugs
BGM0504
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20261844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261844.